Summary: Week of 4/12/25
Biobot’s national wastewater network shows that COVID-19, influenza A, and RSV are decreasing in week 15 (through April 12, 2025), while influenza B is increasing. National hospitalizations for COVID-19, influenza, and RSV continue to decrease, currently at 1.6, 1.5, and 0.8 per 100,000 people in week 14 (through April 5, 2025).
The Bottom Line: We are getting closer to the end of the respiratory season but flu activity remains elevated — we can expect a couple of more weeks of transmission. It’s good to remember these recommendations to stay healthy: stay current with vaccinations, consider wearing a mask in crowded areas, and if you feel unwell, minimize contact with others.
National Outlook
COVID-19
National SARS-CoV-2 concentrations are decreasing.
Influenza
National influenza A concentrations are decreasing, while influenza B is increasing.
RSV
National RSV concentrations are decreasing.
Regional
The South
COVID-19: SARS-CoV-2 concentrations are decreasing in the South.
Influenza: Influenza A concentrations are decreasing in the South, while influenza B is holding steady.
RSV: RSV concentrations are decreasing in the South.
The Midwest
COVID-19: SARS-CoV-2 concentrations are decreasing in the Midwest.
Influenza: Influenza A concentrations are decreasing in the Midwest, while influenza B is increasing.
RSV: RSV concentrations are fluctuating at low levels in the Midwest.
The Northeast
COVID-19: SARS-CoV-2 concentrations are decreasing in the Northeast.
Influenza: Influenza A concentrations are decreasing in the Northeast, while influenza B is increasing.
RSV: RSV concentrations are decreasing in the Northeast.
The West
COVID-19: SARS-CoV-2 concentrations are holding steady in the West.
Influenza: Influenza A concentrations are decreasing in the West, while influenza B is increasing.
RSV: RSV concentrations are decreasing in the West.
Footnotes:
We continue to monitor the evolving H5N1 influenza virus situation, and can now test samples specifically for H5 (including H5N1) — see our blog here and please reach out to hello@biobot.io if interested. A quick reminder that Biobot’s influenza A assay described in this report includes the H5N1 influenza subtype, which is an influenza A virus, but does not distinguish between the different subtypes of influenza A (e.g. H5N1 vs H1N1). We will share any important updates as we have them via Bluesky and in the risk reports.
Wastewater data from Biobot Analytics for RSV, influenza, and SARS-CoV-2 are through April 12, 2025 (MMWR week 15). Clinical data for RSV, influenza, and COVID-19 are from the Centers for Disease Control and Prevention. Updates to clinical data are through April 5, 2025 (MMWR week 14).